Global Omeprazole Market Analysis - 2018-2027
Omeprazole is usually prescribed as proton pump inhibitor (PPI), which helps to reduce acidity. It is mainly used for the treatment of heartburn as well as for the symptoms related to gastroesophageal reflux disease. Omeprazole is also widely used as a combination drug with antibiotics like amoxicillin and clarithromycin for the treatment of ulcers caused by H. pylori bacteria. The global omeprazole market is anticipated to achieve a CAGR of around 6% during the forecast period, i.e. 2019-2027. Factors such as growing prevalence of acid refluxes, respiratory disorders, heart-related issues and others amongst the growing number of elderly populations, increasing opportunities generated from the increasing focus on innovation and development for low-cost generics by the pharmaceutical manufacturers and rising number of obese people globally are anticipated to contribute towards the growth of the global omeprazole market. Additionally, factors such as increasing awareness for the treatment of several gastrointestinal disorders amongst individuals, coupled with the rising number of patients who are suffering from peptic ulcers are some of the factors anticipated to drive the growth of the global omeprazole market.
The global omeprazole market consists of various segments that are segmented by dosage form, distribution channel, indication and by region. The distribution channel segment is further sub-divided into hospital, retail and online. Out of these, the hospital segment, which had a market value of around USD 900 million in the year 2018 is anticipated to hold the largest market share by the end of 2027 and cross a value of around USD 1500 million by growing at a CAGR of around 6.5% over the forecast period.
Based on region, the global omeprazole market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market in Asia Pacific, which had a value of around USD 420 million in the year 2018 is anticipated to grow at a moderate pace over the forecast period and cross a value of around USD 770 million by the end of 2027.
Some of the affluent industry leaders in the global omeprazole market are Dr. Reddy’s Laboratories Ltd., AstraZeneca plc, Sandoz International GmbH, Mylan N.V., Apotex, Inc., Amneal Pharmaceuticals LLC, Perrigo Company plc, Salix Pharmaceuticals and Allergan plc.
Omeprazole is usually prescribed as proton pump inhibitor (PPI), which helps to reduce acidity. It is mainly used for the treatment of heartburn as well as for the symptoms related to gastroesophageal reflux disease. Omeprazole is also widely used as a combination drug with antibiotics like amoxicillin and clarithromycin for the treatment of ulcers caused by H. pylori bacteria. The global omeprazole market is anticipated to achieve a CAGR of around 6% during the forecast period, i.e. 2019-2027. Factors such as growing prevalence of acid refluxes, respiratory disorders, heart-related issues and others amongst the growing number of elderly populations, increasing opportunities generated from the increasing focus on innovation and development for low-cost generics by the pharmaceutical manufacturers and rising number of obese people globally are anticipated to contribute towards the growth of the global omeprazole market. Additionally, factors such as increasing awareness for the treatment of several gastrointestinal disorders amongst individuals, coupled with the rising number of patients who are suffering from peptic ulcers are some of the factors anticipated to drive the growth of the global omeprazole market.
The global omeprazole market consists of various segments that are segmented by dosage form, distribution channel, indication and by region. The distribution channel segment is further sub-divided into hospital, retail and online. Out of these, the hospital segment, which had a market value of around USD 900 million in the year 2018 is anticipated to hold the largest market share by the end of 2027 and cross a value of around USD 1500 million by growing at a CAGR of around 6.5% over the forecast period.
Based on region, the global omeprazole market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market in Asia Pacific, which had a value of around USD 420 million in the year 2018 is anticipated to grow at a moderate pace over the forecast period and cross a value of around USD 770 million by the end of 2027.
Some of the affluent industry leaders in the global omeprazole market are Dr. Reddy’s Laboratories Ltd., AstraZeneca plc, Sandoz International GmbH, Mylan N.V., Apotex, Inc., Amneal Pharmaceuticals LLC, Perrigo Company plc, Salix Pharmaceuticals and Allergan plc.
Table of Contents
Global Omeprazole Market13. Acronyms
1. Report Overview
2. Introduction to the Omeprazole Market
3. Global Omeprazole Market, By Dosage Form, 2019-2027
4. Global Omeprazole Market, By Distribution Channel, 2019-2027
5. Global Omeprazole Market, By Indication, 2019-2027
6. Global Omeprazole Market, By Region, 2019-2027
7. North America Omeprazole Market Analysis and Forecast, 2019-2027
8. Latin America Omeprazole Market Analysis and Forecast, 2019-2027
9. Europe Omeprazole Market Analysis and Forecast, 2019-2027
10. Asia Pacific Omeprazole Market Analysis and Forecast, 2019-2027
11. Middle East & Africa Omeprazole Market Analysis and Forecast, 2019-2027
12. Company Profiles
Companies Mentioned
- Dr. Reddy’s Laboratories Ltd.
- AstraZeneca plc
- Sandoz International GmbH
- Mylan N.V.
- Apotex Inc.
- Amneal Pharmaceuticals LLC
- Perrigo Company plc
- Salix Pharmaceuticals
- Allergan plc
